Unknown

Dataset Information

0

3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.

ABSTRACT: Mcl-1, an antiapoptotic member of the Bcl-2 family of proteins, is a validated and attractive target for cancer therapy. Overexpression of Mcl-1 in many cancers results in disease progression and resistance to current chemotherapeutics. Utilizing high-throughput screening, compound 1 was identified as a selective Mcl-1 inhibitor and its binding to the BH3 binding groove of Mcl-1 was confirmed by several different, but complementary, biochemical and biophysical assays. Guided by structure-based drug design and supported by NMR experiments, comprehensive SAR studies were undertaken and a potent and selective inhibitor, compound 21, was designed which binds to Mcl-1 with a Ki of 180 nM. Biological characterization of 21 showed that it disrupts the interaction of endogenous Mcl-1 and biotinylated Noxa-BH3 peptide, causes cell death through a Bak/Bax-dependent mechanism, and selectively sensitizes E?-myc lymphomas overexpressing Mcl-1, but not E?-myc lymphoma cells overexpressing Bcl-2. Treatment of human leukemic cell lines with compound 21 resulted in cell death through activation of caspase-3 and induction of apoptosis.

SUBMITTER: Abulwerdi FA 

PROVIDER: S-EPMC4033665 | biostudies-literature | 2014 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.

Abulwerdi Fardokht A FA   Liao Chenzhong C   Mady Ahmed S AS   Gavin Jordan J   Shen Chenxi C   Cierpicki Tomasz T   Stuckey Jeanne A JA   Showalter H D Hollis HD   Nikolovska-Coleska Zaneta Z  

Journal of medicinal chemistry 20140507 10

Mcl-1, an antiapoptotic member of the Bcl-2 family of proteins, is a validated and attractive target for cancer therapy. Overexpression of Mcl-1 in many cancers results in disease progression and resistance to current chemotherapeutics. Utilizing high-throughput screening, compound 1 was identified as a selective Mcl-1 inhibitor and its binding to the BH3 binding groove of Mcl-1 was confirmed by several different, but complementary, biochemical and biophysical assays. Guided by structure-based d  ...[more]

Similar Datasets

Unknown Structure-based design of N-substituted 1-hydroxy-4-sulfamoyl-2-naphthoates as selective inhibitors of the Mcl-1 oncoprotein.
| S-EPMC4811700 | biostudies-literature
Unknown 2-amido-3-(1H-indol-3-yl)-N-substituted-propanamides as a new class of falcipain-2 inhibitors. 1. Design, synthesis, biological evaluation and binding model studies.
| S-EPMC6253880 | biostudies-literature
Unknown Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors.
| S-EPMC3472523 | biostudies-literature
Unknown Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.
| S-EPMC4025772 | biostudies-other
Unknown Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.
| S-EPMC4266361 | biostudies-literature
Unknown Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1/Bcl-xL inhibitors.
| S-EPMC4445146 | biostudies-literature
Unknown Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.
| S-EPMC2538619 | biostudies-literature
Unknown Design, synthesis and SAR exploration of tri-substituted 1,2,4-triazoles as inhibitors of the annexin A2-S100A10 protein interaction.
| S-EPMC4182301 | biostudies-literature
Unknown Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors.
| S-EPMC3748591 | biostudies-literature
Unknown (R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.
| S-EPMC4434478 | biostudies-literature